Indeed, there exist several reports on the pre-clinical activity of Akt, PI3K, and mTOR inhibitors in GBM models, and several clinical trials have been initiated with these novel agents [11], [44], [45]. This evidence concerns the gene PIK3CB and glioblastoma.